ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) have received an average rating of “Moderate Buy” from the six analysts that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $28.20.

A number of equities research analysts recently weighed in on the stock. Wall Street Zen upgraded shares of ARS Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Leerink Partners lowered their price objective on ARS Pharmaceuticals from $25.00 to $24.00 and set an “outperform” rating for the company in a research note on Thursday, June 25th. Cantor Fitzgerald raised their target price on ARS Pharmaceuticals from $12.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, May 28th. Finally, Weiss Ratings cut ARS Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, August 17th.

ARS Pharmaceuticals News Roundup

Here are the key news stories impacting ARS Pharmaceuticals this week:

• Negative Sentiment: Multiple firms, including Rosen Law Firm, Kaplan Fox, Faruqi & Faruqi, and others, are soliciting investors who purchased SPRY shares between March 9 and June 24, 2026, in connection with a securities class action. The litigation creates potential legal costs, reputational risk, and uncertainty for shareholders. Rosen Law Firm class action announcement
• Negative Sentiment: The allegations reportedly focus on whether ARS adequately disclosed the risk that CVS Caremark’s formulary process could delay coverage for neffy until January 2027. A delay could cause the product to miss the summer and back-to-school allergy seasons, potentially weighing on near-term sales expectations. SueWallSt ARS investor alert
• Neutral Sentiment: The October 5 deadline is procedural and does not establish that ARS violated securities laws; the allegations remain unproven. Investors who qualify may seek lead-plaintiff status or participate through the litigation process without upfront legal fees. SBS ARS securities lawsuit announcement

ARS Pharmaceuticals Price Performance

Shares of SPRY opened at $5.62 on Friday. The business’s fifty day moving average is $6.47 and its 200 day moving average is $7.88. ARS Pharmaceuticals has a 12-month low of $4.91 and a 12-month high of $13.15. The company has a quick ratio of 3.28, a current ratio of 3.48 and a debt-to-equity ratio of 13.72. The stock has a market cap of $558.89 million, a P/E ratio of -2.58 and a beta of 1.05.

ARS Pharmaceuticals (NASDAQ:SPRY) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.15). ARS Pharmaceuticals had a negative net margin of 184.24% and a negative return on equity of 256.67%. The business had revenue of $33.66 million for the quarter, compared to the consensus estimate of $31.32 million. Sell-side analysts anticipate that ARS Pharmaceuticals will post -1.9 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other ARS Pharmaceuticals news, insider Alexander Fitzpatrick sold 3,355 shares of the firm’s stock in a transaction on Friday, June 12th. The stock was sold at an average price of $10.00, for a total transaction of $33,550.00. Following the transaction, the insider directly owned 90,910 shares in the company, valued at approximately $909,100. This trade represents a 3.56% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Eric Karas sold 25,000 shares of ARS Pharmaceuticals stock in a transaction on Friday, June 12th. The stock was sold at an average price of $10.00, for a total transaction of $250,000.00. Following the transaction, the insider directly owned 12,176 shares in the company, valued at $121,760. This represents a 67.25% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 33.80% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SPRY. Allianz Asset Management GmbH purchased a new stake in ARS Pharmaceuticals in the 2nd quarter valued at about $82,000. Corient Private Wealth LP lifted its holdings in ARS Pharmaceuticals by 12.5% during the second quarter. Corient Private Wealth LP now owns 91,042 shares of the company’s stock worth $729,000 after acquiring an additional 10,099 shares during the period. California State Teachers Retirement System boosted its position in ARS Pharmaceuticals by 588.5% in the second quarter. California State Teachers Retirement System now owns 369,445 shares of the company’s stock worth $2,959,000 after purchasing an additional 315,787 shares during the last quarter. Syon Capital LLC bought a new position in ARS Pharmaceuticals in the 2nd quarter valued at $80,000. Finally, Headlands Technologies LLC increased its position in shares of ARS Pharmaceuticals by 56.2% during the 2nd quarter. Headlands Technologies LLC now owns 75,279 shares of the company’s stock valued at $603,000 after purchasing an additional 27,073 shares during the last quarter. 68.16% of the stock is currently owned by hedge funds and other institutional investors.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.